Literature DB >> 18032747

Atrophy rates accelerate in amnestic mild cognitive impairment.

C R Jack1, S D Weigand, M M Shiung, S A Przybelski, P C O'Brien, J L Gunter, D S Knopman, B F Boeve, G E Smith, R C Petersen.   

Abstract

BACKGROUND: We tested if rates of brain atrophy accelerate in individuals with amnestic mild cognitive impairment (aMCI) as they progress to typical late onset Alzheimer disease (AD). We included comparisons to subjects with aMCI who did not progress (labeled aMCI-S) and also to cognitively normal elderly subjects (CN).
METHODS: We studied 46 subjects with aMCI who progressed to AD (labeled aMCI-P), 46 CN, and 23 aMCI-S. All subjects must have had three or more serial MRI scans. Rates of brain shrinkage and ventricular expansion were measured across all available serial MRI scans in each subject. Change in volumes relative to the point at which subjects progressed to a clinical diagnosis of AD (the index date) was modeled in aMCI-P. Change in volumes relative to age was modeled in all three clinical groups.
RESULTS: In aMCI-P the change in pre to post index rate (i.e., acceleration) of ventricular expansion was 1.7 cm(3)/year, and acceleration in brain shrinkage was 5.3 cm(3)/year. Brain volume declined and ventricular volume increased in all three groups with age. Volume changes decelerated with increasing age in aMCI-P, and to a lesser extent in aMCI-S, but were linear in the matched CN. Among all subjects with aMCI, rates of atrophy were greater in apolipoprotein E epsilon 4 carriers than noncarriers.
CONCLUSIONS: Rates of atrophy accelerate as individuals progress from amnestic mild cognitive impairment (aMCI) to typical late onset Alzheimer disease (AD). Rates of atrophy are greater in younger than older subjects with aMCI who progressed to AD and subjects with aMCI who did not progress. We did not find that atrophy rates varied with age in 70- to 90-year-old cognitively normal subjects.

Entities:  

Mesh:

Year:  2007        PMID: 18032747      PMCID: PMC2734477          DOI: 10.1212/01.wnl.0000281688.77598.35

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  56 in total

1.  Quantitative volumetric analysis of brain MR: normative database spanning 5 decades of life.

Authors:  D D Blatter; E D Bigler; S D Gale; S C Johnson; C V Anderson; B M Burnett; N Parker; S Kurth; S D Horn
Journal:  AJNR Am J Neuroradiol       Date:  1995-02       Impact factor: 3.825

2.  A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging.

Authors:  P Scheltens; F Barkhof; D Leys; J P Pruvo; J J Nauta; P Vermersch; M Steinling; J Valk
Journal:  J Neurol Sci       Date:  1993-01       Impact factor: 3.181

3.  A method for using MR to evaluate the effects of cardiovascular disease on the brain: the cardiovascular health study.

Authors:  R N Bryan; T A Manolio; L D Schertz; C Jungreis; V C Poirier; A D Elster; R A Kronmal
Journal:  AJNR Am J Neuroradiol       Date:  1994-10       Impact factor: 3.825

4.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

5.  Initial clinical experience in MR imaging of the brain with a fast fluid-attenuated inversion-recovery pulse sequence.

Authors:  J N Rydberg; C A Hammond; R C Grimm; B J Erickson; C R Jack; J Huston; S J Riederer
Journal:  Radiology       Date:  1994-10       Impact factor: 11.105

Review 6.  Staging of Alzheimer-related cortical destruction.

Authors:  H Braak; E Braak; J Bohl
Journal:  Eur Neurol       Date:  1993       Impact factor: 1.710

7.  MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease.

Authors:  C R Jack; R C Petersen; P C O'Brien; E G Tangalos
Journal:  Neurology       Date:  1992-01       Impact factor: 9.910

8.  Cognitive decline in Alzheimer's disease: a longitudinal investigation of risk factors for accelerated decline.

Authors:  L Teri; S M McCurry; S D Edland; W A Kukull; E B Larson
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1995-01       Impact factor: 6.053

9.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  A longitudinal study of brain morphometrics using quantitative magnetic resonance imaging and difference image analysis.

Authors:  R S N Liu; L Lemieux; G S Bell; S M Sisodiya; S D Shorvon; J W A S Sander; J S Duncan
Journal:  Neuroimage       Date:  2003-09       Impact factor: 6.556

View more
  81 in total

1.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.

Authors:  A Caroli; G B Frisoni
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

2.  Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.

Authors:  Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Val Lowe; Kejal Kantarci; Matt A Bernstein; Matthew L Senjem; Jeffrey L Gunter; Bradley F Boeve; John Q Trojanowski; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; David S Knopman
Journal:  Arch Neurol       Date:  2012-07

Review 3.  Quantitative structural MRI for early detection of Alzheimer's disease.

Authors:  Linda K McEvoy; James B Brewer
Journal:  Expert Rev Neurother       Date:  2010-11       Impact factor: 4.618

4.  Fluorodeoxyglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years.

Authors:  José V Pardo; Joel T Lee; Michael A Kuskowski; Kristin R Munch; John V Carlis; Sohail A Sheikh; Christa Surerus; Scott M Lewis; J Riley McCarten; Howard Fink; Susan McPherson; Hemant H Shah; Susan Rottunda; Maurice W Dysken
Journal:  Alzheimers Dement       Date:  2010-05-06       Impact factor: 21.566

5.  Cortical gray matter atrophy in healthy aging cannot be explained by undetected incipient cognitive disorders: a comment on Burgmans et al. (2009).

Authors:  Anders M Fjell; Lars T Westlye; Thomas Espeseth; Ivar Reinvang; Anders M Dale; Dominic Holland; Kristine B Walhovd
Journal:  Neuropsychology       Date:  2010-03       Impact factor: 3.295

6.  Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort.

Authors:  Shannon L Risacher; Li Shen; John D West; Sungeun Kim; Brenna C McDonald; Laurel A Beckett; Danielle J Harvey; Clifford R Jack; Michael W Weiner; Andrew J Saykin
Journal:  Neurobiol Aging       Date:  2010-08       Impact factor: 4.673

7.  Cognitive correlates of cross-sectional differences and longitudinal changes in trail making performance.

Authors:  Timothy A Salthouse
Journal:  J Clin Exp Neuropsychol       Date:  2010-09-23       Impact factor: 2.475

Review 8.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

Review 9.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

10.  Mild cognitive impairment: searching for the prodrome of Alzheimer's disease.

Authors:  Paul B Rosenberg; Constantine Lyketsos
Journal:  World Psychiatry       Date:  2008       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.